Scientists reported that imatinib, an Abl tyrosine kinase inhibitor, robustly decreased SARS-CoV-2 infection and uncovered a mechanism of action.
[Scientific Reports]
Sorry, but the selected Zotpress account can't be found.
Home Newsletters Immunology of Infectious Disease News Imatinib Inhibits SARS-CoV-2 Infection by an Off-Target-Mechanism
